News
Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.
Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.
2d
Investor's Business Daily on MSNLENZ Therapeutics Shows Rising Price Performance With Jump To 85 RS RatingWhen putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...
5h
The Brighterside of News on MSNNew eye drops could replace reading glasses for millionsThe Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...
The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...
The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...
Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.
The Food and Drug Administration has approved Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in ...
Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...
Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...
Our data shows VIZZ (aceclidine 1.44%) received FDA approval in July 2025, positioning the once-daily, preservative-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results